Suramin as a Chemosensitizer: Oral Pharmacokinetics in Rats

[1]  Kiyoshi Yamaoka,et al.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  F. Boccardo,et al.  Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study , 2005, Journal of Cancer Research and Clinical Oncology.

[3]  M. Wientjes,et al.  Low-dose suramin enhances antitumor activity of mitomycin C in bladder tumors , 2004 .

[4]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[5]  J. Au,et al.  Absorption of 2′, 3′-Dideoxyinosine from Lower Gastrointestinal Tract in Rats and Kinetic Evidence of Different Absorption Rates in Colon and Rectum , 1993, Pharmaceutical Research.

[6]  David C. Smith,et al.  Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma , 2004, Investigational New Drugs.

[7]  M. Grever,et al.  Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Grever,et al.  P-229 Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients , 2003 .

[9]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[10]  M. Wientjes,et al.  Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  M. Wientjes,et al.  Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. , 2001, Cancer research.

[12]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[13]  C. Lathia,et al.  Distribution of [14C]suramin in tissues of male rats following a single intravenous dose. , 2000, Life sciences.

[14]  J. Au,et al.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Small,et al.  Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Rodenhuis,et al.  Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy , 2000, Cancer Chemotherapy and Pharmacology.

[17]  S. Ricci,et al.  Suramin in combination with weekly epirubicin for patients with advanced hormone‐refractory prostate carcinoma , 1999, Cancer.

[18]  R. Danesi,et al.  Suramin in Combination with 5-Fluorouracil (5-FU) and Leucovorin (LV) in Metastatic Colorectal Cancer Patients Resistant to 5-FU+LV-Based Chemotherapy , 1998, Tumori.

[19]  P. Nwonu,et al.  Clinical pharmacokinetics of suramin in patients with onchocerciasis , 1998, European Journal of Clinical Pharmacology.

[20]  J. Beijnen,et al.  Degradation of suramin in aqueous solutions , 1997 .

[21]  C. Coleman,et al.  Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. , 1997, Radiation research.

[22]  J. Bergh,et al.  Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. , 1997, Acta oncologica.

[23]  M. Kassack,et al.  Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues. , 1996, Journal of chromatography. B, Biomedical applications.

[24]  A. Belldegrun,et al.  Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. N. Coleman,et al.  Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpoint. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Kassack,et al.  Stability of Suramin in Aqueous Solution; Possible Implications for the Search for Suramin Metabolites in Patients , 1996, Archiv der Pharmazie.

[27]  E. Zuhowski,et al.  Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Melamed,et al.  Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells. , 1994, Biochemical and biophysical research communications.

[29]  E. Dmitrovsky,et al.  Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial , 1993, Cancer.

[30]  J. Raats,et al.  Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Wilting,et al.  Recent research on the biological activity of suramin. , 1993, Pharmacological reviews.

[32]  C. Stein,et al.  Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. , 1993, Cancer research.

[33]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[34]  R. Motzer,et al.  Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. , 1992, Cancer research.

[35]  H. Scher,et al.  Use of adaptive control with feedback to individualize suramin dosing. , 1992, Cancer research.

[36]  Frederick H. Martini,et al.  Fundamentals of Anatomy & Physiology , 1989 .

[37]  H L Pearce,et al.  Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. , 1988, Molecular pharmacology.

[38]  R. Redfield,et al.  Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection , 1986, Journal of clinical pharmacology.

[39]  J. Collins,et al.  Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography , 1985 .

[40]  C. C. Francis,et al.  Fundamentals of Anatomy , 1938 .